Selected Genmab Literature 

De Weers, M., Y.-T. Tai, M.S. van der Veer, J.M. Bakker, T. Vink, D.C.H. Jacobs, L.A. Oomen, M. Peipp, T. Valerius, J.W. Slootstra, T. Mutis, W.K. Bleeker, K.C. Anderson, H.M. Lokhorst, J.G.J. van de Winkel, and P.W.H.I. Parren. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, effectively induces killing of multiple myeloma tumor cells. J. Immunol. 2011; 186: 1840-1848.

Lammerts van Bueren, J.J., T. Rispens, S. Verploegen, T. van der Palen-Merkus, A.L. Turinsky, S. Stapel, L.J. Workman. H. James, P.H.C. van Berkel, J.G.J. van de Winkel, T.A.E. Platts-Mills, and P.W.H.I. Parren. Anti-galactose-α-1,3-galactose IgE from allergic patients does not bind α-galactosylated glycans on intact therapeutic antibody Fc domains. Nature Biotechnol. 2011; 29: 574-576.

Peipp, M., J.G.J. van de Winkel, and T. Valerius. Molecular engineering to improve antibodies’ anti-lymphoma activity. Best Pract. Res. Clin. Haematol. 2011; 24: 217-229.

Beum, P.V., M.A. Lindorfer, E.M. Peek, P. T. Stukenberg, M. de Weers, F.J. Beurskens, P.W.H.I. Parren, J.G.J. van de Winkel, and R.P. Taylor. Penetration of antibody-opsonized cells by the membrane attack complex of complement promotes calcium influx and induces streamers. Eur. J. Immunol. 2011; 41: 2436-2446.

Beum, P.V., E.M. peek, M.A. Lindorfer, F.J. Beurskens, P.J. Engelberts, P.W.H.I. Paren, J.G.J. van de Winkel, and R.P. Taylor. Loss of CD20 and bound CD20 antibody from opsonized B cells occurs more rapidly because of trogocytosis mediated by Fc receptor-expressing effector cells than direct internalization by the B cells. J. Immunol. 2011; 187: 3438-3447.

Labrijn, A.F., T. Rispens, J. Meesters, R.J. Rose, T.H. den Bleker, S. Loverix, E.T.J. van den Bremer, J. Neijssen, T. Vink, I. Lasters, R.C. Aalberse, A.J.R. Heck, J.G.J. van de Winkel, J. Schuurman, and P.W.H.I. Parren. Species-specific determinants in the immunoglobulin CH3 domain enable Fab-arm exchange by affecting the non-covalent CH3-CH3 interaction strength. J. Immunol. 2011; 187: 3238-3246.

Overdijk M.B., S. Verploegen, J.H. van den Brakel, J.J. Lammerts van Bueren, T. Vink, J.G.J. van de Winkel, P.W.H.I. Parren, and W.K. Bleeker. EGFR antibody induced antibody-dependent cellular cytotoxicity plays a prominent role in inhibiting metastasis and tumorigenesis even of mutated KRAS tumor cells. J. Immunol. 2011; 187: 3383-3390.

Klausz, K., S. Berger, J.J. Lammerts van Bueren, S. Derer, S. Lohse, M. Dechant, J.G.J. van de Winkel, M. Peipp, P.W.H.I. Parren, and T. Valerius. Complement-mediated tumor-specific cell lysis by antibody combinations targeting the epidermal growth factor receptor (EGFR) and its variant III (EGFRvIII). Cancer Sci. 2011; 102: 1761-1768.

Rose R.J., A.F. Labrijn, E.T.J. van den Bremer, S. Loverix, I. Lasters, P.H.C. van Berkel, J.G.J. van de Winkel, J. Schuurman, P.W.H.I. Parren, and A.J.R. Heck. Quantitative analysis of the interaction strength and dynamics of human IgG4 half-molecules by native mass spectrometry. Structure 2011; 19: 1274-1282.

Machiels, J.P., S. Subramanian, A. Ruzsa, G. Repassy, I. Lifirenko, A. Flygare, P. Sorensen, T. Nielsen, S. Lisby, and P.M. Clement. Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of plantinum-based chemotherapy: an open-label, randomised phase 3 trial. Lancet Oncol. 2011; 12: 333-343.

Gramer, M.J., J.J. Eckblad, R. Donahue, J. Brown, K. Vickerman, P. Priem, E.T. van den Bremer, J. Gerritsen, and P.H. van Berkel. Modulation of antibody galactosylation through feeding of uridine, manganese chloride, and galactose. Biotechnol. Bioeng. 2011; 108: 1591-1602.

Taylor, P.C., E. Quattrocchi, S. Mallett, R. Kurrasch, J. Petersen, and D.J. Chang. Ofatumumab, a fully human anti-CD20 mAb, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial. Ann Rheum Dis. 2011; 70: 2119-2125.

Wierda, W.G., S. Padmanabhan, G.W. Chan, I.V. Gupta, S. Lisby, and A. Osterborg. Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from ph II international study. Blood 2011; 118: 5126-5129.

Wierda, W.G., T.J. Kipps, J. Dürig, L. Griskevicius, S. Stilgenbauer, J. Mayer, L. Smolej, G. Hess, R. Griniute, F.J. Hernandez-Ilizaliturri, S. Padmanabhan, M. Gorczyca, C.N. Chang, G. Chan, I. Gupta, T.G. Nielsen, and C.A. Russell; 407 Study Investigators. Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. Blood. 2011; 117: 6450-6458.

Van der Veer, M.S., M. de Weers, B. van Kessel, J.M. Bakker, S. Wittebol, P.W. Parren, H.M. Lokhorst, T. Mutis. Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab. Haematologica. 2011; 96: 284-90.

Kap, Y.S., N. van Driel, E. Blezer, P.W.H.I. Parren, W.K. Bleeker, J.D. Laman, J.L. Craigen, and B.A. 't Hart. Late B Cell Depletion with a Human Anti-Human CD20 IgG1{kappa} Monoclonal Antibody Halts the Development of Experimental Autoimmune Encephalomyelitis in Marmosets. J. Immunol. 2010; 185:3990-4003.

Van Meerten, T. , H. Rozemuller, S. Hol, P. Moerer, M. Zwart, A. Hagenbeek, W.J.M. Mackus, P.W.H.I. Parren, J.G.J. van de Winkel, S.B. Ebeling, and A.C.M. Martens. HuMab-7D8, a monoclonal antibody directed against the membrane-proximal small loop epitope of CD20 can effectively eliminate CD20low expressing tumor cells that resist Rituximab mediated lysis. Haematologica 2010 [Epub ahead of print].

Labrijn A.F., J. Schuurman, J.G.J. van de Winkel, and P.W.H.I. Parren. Reply to Fab Arm exchange (correspondence). Nature Biotechnol. 2010; 28: 125-126.

Østergaard, M., B. Baslund, W. Rigby, B. Rojkovich, C. Jorgensen, P.T. Dawes, C. Wiell, D.J. Wallace, S.C. Tamer, H. Kastberg, J. Petersen, and S. Sierakowski. Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: results of a randomized, double-blind, placebo-controlled, phase I/II study. Arthritis Rheum. 2010; 62: 2227-2238.

Coiffier, B, N. Losic, B.B. Rønn, S. Lepretre, L.M. Pedersen, O. Gadeberg, H. Frederiksen, M.H. van Oers, J. Wooldridge, J. Kloczko, J. Holowiecki, A. Hellmann, J. Walewski, T. Robak, J. Petersen. Pharmacokinetics and pharmacokinetic/pharmacodynamic associations of ofatumumab, a human monoclonal CD20 antibody, in patients with relapsed or refractory chronic lymphocytic leukaemia: a phase 1-2 study. Br. J. Haematol. 2010;150: 58-71.

Wierda, WG, T.J. Kipps, J. Mayer, S. Stilgenbauer, C.D. Williams, A. Hellmann, T. Robak, R.R. Furman, P. Hillmen, M. Trneny, M.J. Dyer, S. Padmanabhan, M. Piotrowska, T. Kozak, G. Chan, R. Davis, N. Losic, J. Wilms, C.A. Russell, and A. Osterborg. Hx-CD20-406 Study Investigators. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J. Clin. Oncol. 2010; 28: 1749-1755.

d’Amore, F., J. Radford, T. Relander, M. Jerkeman, H. Tilly, A. Osterborg, F. Morschhauser, M. Gramatzki, M. Dreyling, B. Bang, and H. Hagberg. Phase II trial of Zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma. Br. J. Haematol. 2010; 150: 565-573.

De Haij, S., J.H.M. Jansen, P. Boross, F.J. Beurskens, J.E. Bakema, D.L. Bos, A. Martens, J.S. Verbeek, P.W.H.I. Parren, J.G.J. van de Winkel, and J.H.W. Leusen. In vivo cytotoxicity of type I CD20 antibodies critically depends on FcR ITAM signaling. Cancer Res. 2010; 70: 3209-3217.

Schneider-Merck, T., J.J. Lammerts van Bueren, S. Berger, K. Rossen, P.H.C. van Berkel, S. Derer, T. Beyer, S. Lohse, W.K. Bleeker, M. Peipp, P.W.H.I. Parren, J.G.J. van de Winkel, T. Valerius, and M. Dechant. Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage. J. Immunol. 2010; 184: 512-520.

Gerritsen, A.F., M. Bosch, M. de Weers, J.G.J. van de Winkel, and P.W.H.I. Parren. High throughput screening for antibody induced complement-dependent cytotoxicity in early antibody discovery using homogeneous macroconfocal fluorescence imaging. J. Immunol. Methods 2010; 352: 140-146.

Van Berkel, P.H.C., J. Gerritsen, E. van Voskuilen, G. Perdok, T. Vink, J.G.J. van de Winkel, and P.W.H.I. Parren. Rapid production of recombinant human IgG with improved ADCC effector function in a transient expression system. Biotechnol. Bioeng. 2009; 105: 350-357.

Van Berkel, P.H.C., J. Gerritsen, G. Perdok, J. Valbjørn, T. Vink, J.G.J. van de Winkel, and P.W.H.I. Parren. N-linked glycosylation is an important parameter for optimal selection of cell lines producing biopharmaceutical human IgG. Biotechnol. Prog. 2009; 25: 244-251.

Raaz D., M. Herrmann, A.B. Ekici, L. Klinghammer, B. Lausen, R.E. Voll, J.H.W. Leusen, J.G.J. van de Winkel, W.G. Daniel, A. Reis, C.D. Garlichs. FcγRIIa genotype is associated with acute coronary syndromes as first manifestation of coronary artery disease. J. Atherosclerosis 2009; 205: 512-516.

Pawluczkowycz, A., F.J. Beurskens, P.V. Beum, M.A. Lindorfer, J.G.J. van de Winkel, P.W.H.I. Parren, and R.P. Taylor. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): Considerably higher levels of CDC are induced by OFA than by RTX. J. Immunol. 2009; 183: 749-758.

Labrijn, A.F., A. Ortiz Buijsse, E.T.J. van den Bremer, A.Y.W. Verwilligen, W.K. Bleeker, S.J. Thorpe, J. Killestein, C.H. Polman, R.C. Aalberse, J. Schuurman, J.G.J. van de Winkel, and P.W.H.I. Parren. Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. Nature Biotechnol. 2009; 27: 767-771.

Ruuls, S., J.J. Lammerts van Bueren, J.G.J. van de Winkel, and P.W.H.I. Parren. Novel human antibody therapeutics: the age of the Umabs. Biotechnol. J. 2008; 3: 1157-1171.

Beurskens, F.J., S.R. Ruuls, P.J. Engelberts, T. Vink, W.J. Mackus, J.G.J. van de Winkel, and P.W.H.I. Parren. Complement activation impacts B-cell depletion by both type I and type II CD20 monoclonal antibodies. Blood 2008; 112: 4354-4355.

Otten, M.A., G.J. van der Bij, S.J. Verbeek, E. Rudolph, F. Nimmerjahn, J.V. Ravetch, R.H.J. Beelen, J.G.J. van de Winkel, and M. van Egmond. Experimental antibody therapy of liver metastases reveals functional reduncancy between FcγRI and FcγRIV. J. Immunol. 2008; 181: 6829-6836.

Hagenbeek A., O. Gadeberg, P. Johnson, L.M. Pedersen, J. Walewski, A. Hellmann, B.K. Link, T. Robak, M. Wojtukiewicz, M. Pfreundschuh, M. Kneba, A. Engert, P. Sonneveld, M. Flensburg, J. Petersen, N. Losic, J. Radford. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood 2008; 111: 5486-5495.

Parren, P.W.H.I., and J.G.J. van de Winkel.  An integrated science-based approach to drug development. Curr. Opin. Immunol. 2008; 20:426-430.

Aarden, L., S.R. Ruuls, and G. Wolbink. Immunogenicity of anti-tumor necrosis factor antibodies - toward improved methods of anti-antibody measurement. Curr. Opin. Immunol. 2008; 20:431-235.

Labrijn, A.F., R.C. Aalberse, and J. Schuurman. When binding is enough: nonactivating antibody formats. Curr. Opin. Immunol. 2008; 20:479-485.

Skov, L., F.J. Beurskens, C.O.C. Zachariae, S. Reitamo, J. Teeling, D. Satijn, K.M. Knudsen, E.P.J. Boot, D. Hudson, O. Baadsgaard, P.W.H.I. Parren, and J.G.J. van de Winkel. IL-8 as antibody therapeutic target in inflammatory diseases: reduction of clinical activity in Palmoplantar Pustulosis. J. Immunol. 2008; 181: 669-679.

Beum P.V., M.A. Lindorfer, F. Beurskens, P.T. Stukenberg, P.W.H.I. Parren, J.G.J. van de Winkel, and R.P. Taylor. Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis. J. Immunol. 2008; 181: 822-832.

Dechant, M., W. Weisner, S. Berger, M. Peipp, T. Beyer, T. Schneider-Merck, J.J. Lammerts van Bueren, W.K. Bleeker, P.W.H.I. Parren, J.G.J. van de Winkel, and T. Valerius. Complement-dependent tumor cell lysis triggered by combinations of Epidermal Growth Factor receptor antibodies. Cancer Research 2008; 68: 4998-5003.

Lammerts van Bueren, J.J., W.K. Bleeker, A. Brännström, A. Von Euler, M. Jansson. M. Peipp, T. Schneider-Merck, T. Valerius, J.G.J. van de Winkel, and P.W.H.I. Parren.  The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra-and inter-molecular flexibility.  Proc. Natl. Acad. Sci USA 2008; 105: 6109-6114.

Wijngaarden, S., J.G.J. van de Winkel, J.W.J. Bijlsma, F.P.J.G. Lafeber, and J.A.G. van Roon.  Treatment of rheumatoid arthritis patients with anti-TNF-α monoclonal antibody is accompanied by down-regulation of activating FcγReceptor I on monocytes. Clin. Exp. Rheumatol. 2008; 26: 89-95.

Beekman, J.M., C.E. van der Poel, J.A. van der Linden, D.L.C. van den Berg, P.V.E. van den Berghe, J.G.J. van de Winkel, and J.H.W. Leusen. Filamin A stabilizes FcγRI surface expression and prevents its lysosomal routing. J. Immunol. 2008, 180: 3938-3945.

Winiarska, M., J. Bil, E. Wilczek, G.M. Wilczynski, M. Lekka, P.J. Engelberts, W.J.M. Mackus, E. Gorska, L. Bojarski, T. Stoklosa, D. Nowis, Z. Kurzaj, M. Makowski, E. Glodkowska, T. Issat, P. Mrowka, W. Lasek, A. Dabrowska-Iwanicka, G.W. Basak, M. Wasik, K. Warzocha, M. Sinski, Z. Gaciong, M. Jakobisiak, P.W.H.I. Parren, and J. Golab. Statins impair antitumor effects of Rituximab by inducing conformational changes of CD20. PLoS Medicine 2008; 5: e64.

Peipp, M., T. Schneider-Merck, M. Dechant, T. Beyer, J.J. Lammerts van Bueren, W.K. Bleeker, P.W.H.I. Parren, J.G.J. van de Winkel, and T. Valerius.  Tumor cell killing mechanisms of EGF-R antibodies are not affected by lung cancer-associated EGF-R kinase mutations.  J.Immunol. 2008; 180: 4338-4345.

Bleeker, W.K., M.E. Munk, W.J.M. Mackus, J.H.N. van den Brakel, M. Pluyter, M.J. Glennie, J.G.J. van de Winkel, and P.W.H.I. Parren. Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody.  Brit. J. Haematol. 2008; 140: 303-312.

Coiffier, B., S. Lepetre, L.M. Pedersen, O. Gadeberg, H. Fredriksen, M.H. van Oers, J. Wooldridge, J. Kloczko, J. Holowiecki, A. Hellmann, J. Walewski, M. Flensburg, J. Pedersen and T. Robak. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood 2008; 111: 1094-1100.

Rider, D.A., C.E.G. Havenith, R. de Ridder. J. Schuurman, C. Favre, J.C. Cooper, S. Walker, O. Baadsgaard, S. Marschner, J.G.J. van de Winkel, J. Cambier, P.W.H.I. Parren, and D.R. Alexander. A human CD4 monoclonal antibody for the treatment of T cell lymphoma combines inhibition of T cell signaling by a dual mechanism with potent Fc-dependent effector activity. Cancer Res. 2007; 67: 9945-53.

Seshasayee, D. W.P. Lee, M. Zhou, J. Shu, E. Suto, J. Zhang, L. Diehl, C.D. Austin, Y.G. Meng, M. Tan, S.L. Bullens, S. Seeber, M.E. Fuentes, A.F. Labrijn, Y.M.F. Graus, L.A. Miller, E.S. Schelegle, D.M. Hyde, L.C. Wu, S.G. Hymowitz, and F. Martin. In vivo blockade of OX40 ligand inhibits thymic stromal lymphopoietin driven atopic inflammation. J. Clin. Invest. 2007; 117: 3868-3878.

McIntosh, R.S., J. Shi, R.M. Jennings, J.C. Chappel, T.F. de Koning-Ward, T. Smith, J. Green, M. van Egmond, J.H.W. Leusen, M. Lazarou, J.G.J. van de Winkel, T.S. Jones, B.S. Crabb, A.A. Holder, and R.J. Pleass. The importance of human FcγRI in mediating protection to malaria. PloS Pathogens 2007; 3: e72.

Dechant, M., T. Beyer, T. Schneider-Merck, W. Weisner, M. Peipp, J.G.J. van de Winkel, and T. Valerius. Effector mechanisms of recombinant IgA antibodies against Epidermal Growth Factor Receptor. J. Immunol. 2007; 179: 2936-2943.

Otten, M.A., J.H.W. Leusen, E. Rudolph, J.A. van der Linden, R.H.J. Beelen, J.G.J. van de Winkel, and M. van Egmond. FcR γ chain dependent signaling in immature neutrophils is mediated by FcαRI, but not by FcγRI. J. Immunol. 2007; 179: 2918-2924.

Hessell, A.J., L. Hangartner, M. Hunter, C.E.G. Havenith, F.J. Beurskens, J.M. Bakker, C.M.S. Lanigan, G. Landucci, D.N. Forthal, P.W.H.I. Parren, P.A. Marx, and D.R. Burton. Nature 2007; 449: 101-104.

van der Neut Kolfschoten, M., J. Schuurman, M. Losen, W.K. Bleeker, P. Martinez-Martinez, E. Vermeulen, T.H. den Bleker, L. Wiegman, T. Vink, L.A. Aarden, M.H. De Baets, J.G.J. van de Winkel, R.C. Aalberse, P.W.H.I. Parren. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 2007; 317: 1554-1557.

Kim, Y.H., M. Duvic, E. Obitz, R. Gniadecki, L. Iversen, A. Osterborg, S. Whittaker, T.M. Illidge, T. Schwarz, R. Kaufmann, K. Cooper, K.M. Knudsen, S. Lisby, O. Baadsgaard, and S.J. Knox. Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood 2007; 109: 4655-4662.

Villadsen, L.S., L. Skov, T.N. Dam, F. Dagnaes-Hansen, J. Rygaard, J. Schuurman, P.W.H.I. Parren. J.G.J. van de Winkel, and O. Baadsgaard. In situ depletion of CD4+ cells in human skin by Zanolimumab. Arch. Dermatol. Res. 2007; 298: 449-455.

Bakema, J.E., S. De Haij, C.F. den Hartog-Jager, J. Bakker, G. Vidarsson, M. Van Egmond, J.G.J. van de Winkel, and J.H.W. Leusen. Signaling through mutants of the IgA receptor, CD89, and consequences for FcR γ-chain interaction. J Immunol. 2006; 176: 3603-3610.

Rodriguez, M.E., S.M.M. Hellwig, M.L.A. Perez Vidakovics, G.A.M. Berbers, and J.G.J. van de Winkel. Bordetella pertussis attachment to respiratory epithelial cells can be impaired by Fimbriae-specific antibodies. FEMS Immunol. Med. Microbiol. 2006; 46: 39-47.

Lammerts van Bueren, J.J., W.K. Bleeker, H.O. Bøgh, M. Houtkamp, J. Schuurman, J.G.J. van de Winkel, and P.W.H.I. Parren. Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: implications for the mechanisms of action. Cancer Res. 2006; 66: 7630-7638.

Vidarsson, G., A.M. Stemerding, F.E.M. Rebers, M. de Haas, and J.G.J. van de Winkel. FcRn: an IgG receptor on phagocytes with a novel role in phagocytosis. Blood 2006; 108: 3573-3579.

Bevaart, L., J. Goldstein, L. Vitale, C. Russoniello, J. Treml, J. Zhang, R.F. Graziano, J.H.W. Leusen, J.G.J. van de Winkel, and T. Keler. Direct targeting of genetically modified tumour cells to FcγRI triggers potent tumor cytotoxicity. Brit. J. Haematol. 2006; 132: 317-325.

Bevaart, L., M.J.H. Jansen, M.J. van Vugt, J.S. Verbeek, J.H.W. Leusen, and J.G.J. van de Winkel. The high-affinity IgG receptor, FcγRI, plays a central role in antibody therapy of experimental melanoma. Cancer Res. 2006; 66: 1261-1264.

Teeling, J., W.J.M. Mackus, L.J.J.M. Wiegman, J.H.N. van den Brakel, S.A. Beers, R.R. French, T. van Meerten, S. Ebeling, T. Vink, J.W. Slootstra, P.W.H.I. Parren, M.J. Glennie, and J.G.J. van de Winkel. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J. Immunol. 2006; 177: 362-371.

Van Vuuren, A.J., J. van Roon, V. Walraven, I. Stuij, M.C. Harmsen, J.G.J. van de Winkel, and T. Thepen. CD64-directed immunotoxin inhibits arthritis in a novel CD64 transgenic rat model. J. Immunol. 2006; 176: 5833-5838.

Steeghs, L., S.J. van Vliet, H. Uronen-Hansson, A. van Mourik, A. Engering, M. Sanchez-Hernandez, N. Klein, R. Callard, J.P.M. van Putten, P. van der Ley, Y. van Kooyk, and J.G.J. van de Winkel. Neisseria meningitidis expressing IgtB lipopolysaccharide targets DC-SIGN and modulates dendritic cell function. Cell. Microbiol. 2006; 8: 316-325.

Van Royen, A., E.A.M. Sanders, V. Walraven, M. Voorhorst, E. Saeland, J.L. Teeling, A. Gerritsen, M.A. van dijk, W. Kuis, G.T. Rijkers, L. Vitale, T. Keler, S.E. McKenzie, J.H.W. Leusen, and J.G.J. van de Winkel. Novel human CD32 mAb blocks experimental immune hemolytic anemia in FcγRIIA transgenic mice. Brit. J. Haematol. 2005; 130: 130-137.

Vidarsson, G., N. Overbeeke, A.M. Stemerding, G. van den Dobbelsteen, P. van Ulsen, P. van der Ley, M. Kilian, and J.G.J. van de Winkel. Working mechanism of IgA1-protease: cleavage of IgA1 antibody to PorA of Neisseria meningitidis requires de novo synthesis of IgA1-protease. Infect. Immunity 2005; 73: 6721-6726.

Baslund, B., N. Tvede, B. Danneskiold-Samsoe, P. Larsson, G. Panayi, J. Petersen, L.J. Petersen, F. Beurskens, J. Schuurman, J.G.J. van de Winkel, P.W.H.I. Parren, J. A. Gracie, S. Jongbloed, F.Y. Liew, and I.B. McInnes. Targeting interleukin-15 in patients with rheumatoid arthritis (RA): a proof-of-concept study. Arthritis Rheum. 2005; 52: 2686-2692.

Waldmann, T.A. Targeting the interleukin-15 system in rheumatoid arthritis. Arthritis Rheum. 2005; 52: 2585-2588.

Bevaart, L., H.H. van Ojik, A.W. Sun, T.H. Sulahain, J.H.W. Leusen, G.J. Weiner, J.G.J. van de Winkel and M.J. van Vugt. CpG oligodeoxynucleotides enhance FcγRI-mediated cross presentation by dendritic cells. Int. Immunol. 2004; 16 : 1091-1098.

Beekman, J.M., J. van der Linden, J. Bakema, B. Tops, M. Hinten, M.J. van Vugt, J.G.J. van de Winkel and J.H.W. Leusen. Modulation of FcγRI (CD64) ligand binding by blocking peptides of periplakin. J. Biol. Chem. 2004; 279 : 33875-33881.

Beekman, J.M., J. Bakema, J.H.W. Leusen and J.G.J. van de Winkel. Direct interaction between FcγRI (CD64) and periplakin controls receptor endocytosis and ligand binding capacity. Proc. Natl. Acad. Sci. USA 2004; 101 : 10392-10397.

Bleeker, W.K., J.J. Lammerts van Bueren, H.H. van Ojik, A.F. Gerritsen, M. Pluyter, M. Houtkamp, E. Halk, J. Goldstein, J. Schuurman, M.A. van Dijk, J.G.J. van de Winkel and P.W.H.I. Parren. Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy. J. Immunol. 2004; 173 : 4699-4707.

Teeling, J.L., R.R. French, M.S. Cragg, J. van den Brakel, M. Pluyter, H. Huang, C. Chan, P.W.H.I. Parren, C.E. Hack, M. Dechant, T. Valerius, J.G.J. van de Winkel and M.J. Glennie. Characterisation of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 2004; 104 : 1793-1800.

Villadsen, L.S., L. Skov and O. Baadsgaard. Biological response modifiers and their potential use in the treatment of inflammatory skin diseases. Exp. Dermatol. 2003; 12 : 1-10.

Villadsen, L.S., J. Schuurman, F. Beurskens, T.N. Dam, F. Dagnæs-Hansen, L. Skov, J. Rygaard, M.M. Voorhorst-Ogink, A.F. Gerritsen, M.A. van Dijk, P.W.H.I. Parren, O. Baadsgaard and J.G.J. van de Winkel. Resolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse model. J. Clin. Invest. 2003; 112 : 1571-1580.

Skov, L., K. Kragballe, C. Zachariae, E.R. Obitz, E.A. Holm, G.B. Jemec, H. Solvsten, H.H. Ibsen, L. Knudsen, P. Jensen, J.H. Petersen, T. Menne and O. Baadsgaard. HuMax-CD4: a fully human monoclonal anti-CD4 antibody for the treatment of psoriasis vulgaris. Arch. Dermatol. 2003; 139 : 1433-9.

Van Ojik, H.H., L. Bevaart, C.E. Dahle, A. Bakker, M.J. Jansen, M.J. van Vugt, J.G.J. van de Winkel and G.J. Weiner. CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations. Cancer Res. 2003; 63 : 5595-600.

Parren, P.W.H.I., J.H.W. Leusen and J.G.J. van de Winkel. Antibody-catalyzed water oxidation: state-of-the-art immunity or ancient history? Trends Immunol. 2003; 24 : 467-9.

Hellwig, S.M.M., M.E. Rodriguez, G.A. Berbers, J.G.J. van de Winkel and F.R. Mooi. Crucial role of antibodies to pertactin in Bordetella pertussis immunity. J. Infect. Dis. 2003; 188 : 738-42.

Glennie, M.J. and J.G.J. van de Winkel. Renaissance of cancer therapeutic antibodies. Drug Discov. Today 2003; 8 : 503-510.

Saeland, E., G. Vidarsson, J.H.W. Leusen, E. van Garderen, M.H. Nahm, H. Vile-Weekhout, V. Walraven, A.M. Stemerding, J.S. Verbeek, G.T. Rijkers, W. Kuis, E.A.M. Sanders and J.G.J. van de Winkel. Central role of complement in passive protection by human IgG1 and IgG2 anti-pneumococcal antibodies in mice. J. Immunol. 2003; 170 : 6158-64.

Saeland, E., J.H.W. Leusen, G. Vidarsson, W. Kuis, E.A.M. Sanders, I. Jonsdottir and J.G.J. van de Winkel. Role of Fcγ receptors in vaccine induced immunity to Streptococcus pneumoniae. J. Infect. Dis. 2003; 187 : 1686-93.

Stassen, M.H., F. Meng, E. Melgert, B.M. Machiels, S.H. Im, S. Fuchs, A.F. Gerritsen, M.A. van Dijk, J.G.J. van de Winkel and M.H. de Baets. Experimental autoimmune myasthenia gravis in mice expressing human immunoglobulin loci. J. Neuroimmunol. 2003; 135 : 56-61.

Monteiro, R.C. and J.G.J. van de Winkel. IgA Fc receptors. Annu. Rev. Immunol. 2003; 177-204.

Van Spriel, A.B., H.H. van Ojik, A. Bakker, M.J.H. Jansen and J.G.J. van de Winkel. Mac-1 (CD11b/CD18) is crucial for effective Fc receptor-mediated immunity to melanoma. Blood 2003; 101 : 253-258.

Dechant, M., G. Vidarsson, B. Stockmeyer, R. Repp, M.J. Glennie, M. Gramatzki, J.G.J. van de Winkel and T. Valerius. Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing. Blood 2002; 100 : 4574-4580.

Ioan-Facsinay, A., S.J. de Kimpe, S.M.M. Hellwig, P.L. van Lent, F.M.A. Hofhuis, H.H. van Ojik, C. Sedlik, S.A. da Silveira, J. Gerber, Y.F. de Jong, R. Roozendaal, L.A. Aarden, W.B. van den Berg, T. Saito, D. Mosser, S. Amigorena, C. Izui, G-J.B. van Ommen, M. van Vugt, J.G.J. van de Winkel and J.S. Verbeek. FcγRI (CD64) contributes substantially to severity of arthritis, hypersensitivity responses and protection from bacterial infection. Immunity 2002; 16 : 391-402.